INOTREM S.A.
http://www.inotrem.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From INOTREM S.A.
Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Deal Watch: Amgen Taps Plexium's Expertise In Targeted Protein Degradation
Mersana will help J&J develop antibody-drug conjugates against three targets, while AstraZeneca out-licenses a candidate for peripheral artery disease to Regio.
Finance Watch: Venture Capital On Track For Another Record Year
Private Company Edition: With $8.9bn raised in the second quarter, venture capital investment in biopharma companies reached its second highest quarterly total to date – behind only Q1 of this year. Also, Nimbus Therapeutics raised $105m and European drug developers get in on the VC action.
Coronavirus Notebook: Oxford/AZ Vaccine Nears UK Approval; Argentina OKs Russia's Sputnik V
The latest round-up from the Pink Sheet of developments relating to COVID-19.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics